RedHill Biopharma (RDHL) Inventory (2017 - 2025)

RedHill Biopharma (RDHL) has reported Inventory for 9 consecutive years, with $3.2 million the latest figure, recorded in Q2 2025.

• On a quarterly basis, Inventory fell 16.69% year-over-year to $3.2 million in Q2 2025; TTM through Jun 2025 was $3.2 million, a 16.69% decrease from a year earlier, with the FY2024 full-year figure at $3.7 million, down 16.81% from the prior year.
• Inventory was $3.2 million for Q2 2025 at RedHill Biopharma, down from $3.7 million in the prior quarter.
• Over five years, Inventory peaked at $14.8 million in Q4 2021 and troughed at $3.2 million in Q2 2025.
• A 5-year average of $8.7 million and a median of $9.0 million in 2021 frame the typical range for Inventory.
• Across the five-year window, Inventory jumped 235.02% in 2021 and tumbled 60.13% in 2023, its largest moves.
• Over 5 years, Inventory stood at $14.8 million in 2021, then retreated by 25.67% to $11.0 million in 2022, then plunged by 60.13% to $4.4 million in 2023, then fell by 16.81% to $3.7 million in 2024, then decreased by 13.2% to $3.2 million in 2025.
• The last three Inventory figures came in at $3.2 million (Q2 2025), $3.7 million (Q4 2024), and $3.8 million (Q2 2024), per Business Quant data.